Recommended dosage for adults and pediatric patients 12 years and older with hepatic impairment
The recommended dosage of Oxbryta in adults and pediatric patients 12 years and older with severe hepatic impairment (Child-Pugh C) is 1,000 mg orally once daily
No dosage adjustment of Oxbryta is required for patients with mild or moderate hepatic impairment
Recommended dosage of Oxbryta for adults and pediatric patients 12 years and older when used with concomitant strong or moderate CYP3A4 inducers
Avoid concomitant use of strong or moderate CYP3A4 inducers with Oxbryta
If concomitant use of strong CYP3A4 inducers is unavoidable, the recommended dosage of Oxbryta is 2,500 mg orally once daily. If concomitant use of moderate CYP3A4 inducers is unavoidable, the recommended dosage of Oxbryta is 2,000 mg orally once daily
Dosing recommendations for Oxbryta in pediatric patients ages 4 to less than 12 years is based on patient's ability to swallow tablets and patient weight
Once daily
If a dose is missed or entire dose is not taken, resume dosing the following day
Recommended Oxbryta Dosage in Pediatric Patients 4 to less than 12 years
For pediatric patients 4 years and older, select the appropriate product (Oxbryta tablets or Oxbryta tablets for oral suspension) based on patient's ability to swallow tablets and patient weight.
Immediately before administration, disperse tablets for oral suspension in room temperature clear liquid (such as drinking water or clear soda) in a cup:
OXBRYTA 300 mg Tablets for Oral Suspension
Recommended Daily Dose
Number of Tablets for Oral Suspension
Minimum Recommended Volume of Clear Drink
300 mg
1
5 mL (1 teaspoon)
600 mg
2
10 mL (2 teaspoons)
900 mg
3
15 mL (3 teaspoons)
1,200 mg
4
20 mL (4 teaspoons)
1,500 mg
5
25 mL (5 teaspoons)
2,100 mg
7
35 mL (7 teaspoons)
2,400 mg
8
40 mL (8 teaspoons)
After the tablets start to disintegrate, swirl the contents of the cup until the tablets are dispersed, wait 1 to 5 minutes, swirl the contents of the cup again, and then orally administer the contents of the cup. The tablet(s) will not completely dissolve; there will still be small tablet clumps in the mixture.
Resuspend any residue left in the cup in more clear drink and administer. Repeat until no tablet residue is left in the cup.
Tablets for oral suspension may be substituted for tablets in adults and pediatric patients 12 years and older with difficulty swallowing the tablets. Use the number of tablets for oral suspension needed to achieve the recommended dose.
You are now leaving Global Blood Therapeutics’ site and moving to an external website independently operated and not managed by Global Blood Therapeutics. Global Blood Therapeutics assumes no responsibility for the site(s) you're visiting. If you do not wish to leave this site, click Cancel, or click OK to continue.
A message from Dr. Ted W. Love
President and CEO, Global Blood Therapeutics, Inc.
Thank you for visiting the virtual 62nd ASH® Annual Meeting and Exposition!
Thank you for visiting the virtual 62nd ASH® Annual Meeting and Exposition!
We are proud to participate in this important meeting and appreciate your interest in learning more about GBT and Oxbryta® (voxelotor) tablets. We at GBT share your passion and commitment to improving the lives of patients. Together, we can make a difference.
I encourage you to explore our website to learn more about Oxbryta.
Some of the uses or data for Oxbryta® (voxelotor) tablets described in the attached journal article have not been approved by the Food & Drug Administration.
NEJM does not hold itself responsible for statements made by any contributor. Statements or opinions expressed in NEJM reflect the views of the author(s) and not the official policy of the Massachusetts Medical Society unless so stated. NEJM reprints are not intended as the sole source of clinical information on this topic. Readers are advised to search the NEJM website at www.nejm.org and other medical sources for relevant clinical information on this topic. Reprints of articles published in NEJM are distributed only as free-standing educational material. They are not intended to endorse or promote any organization or its products or services.
If you do not wish to leave this site, click Cancel, or click Ok to continue.